Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (INR)83.05
  • Today's Change0.55 / 0.67%
  • Shares traded258.92k
  • 1 Year change-60.45%
  • Beta1.8647
Data delayed at least 15 minutes, as of Feb 03 2023 10:15 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Events & Activity

  • DCAL:NSI price reached a new 52-week low of 80.95 at 12:33 GMT
  • DCAL:NSI price reached a new 52-week low of 82.20 at 13:38 GMT
  • DCAL:NSI price moved over +3.48% to 87.75
  • DCAL:NSI trading volume exceeds daily average by +23.42%

Key statistics

On Friday, Dishman Carbogen Amcis Ltd (DCAL:NSI) closed at 83.05, 3.81% above its 52-week low of 80.00, set on Feb 03, 2023.
52-week range
80.00Feb 03 2023218.90Feb 04 2022
Previous close82.50
Average volume221.26k
Shares outstanding156.78m
Free float48.11m
P/E (TTM)--
Market cap13.02bn INR
EPS (TTM)-0.968
Data delayed at least 15 minutes, as of Feb 03 2023 10:15 GMT.
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.